These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36172878)

  • 1. Trends in oral anticoagulant prescription in patients with nonvalvular atrial fibrillation in Flanders and the impact of switching patients from vitamin K antagonists to DOACS in terms of the burden caused by complications of the disease: a registry-based study.
    Nakhoul E; Vaes B; Mamouris P; Degryse JM
    Acta Clin Belg; 2023 Aug; 78(4):261-269. PubMed ID: 36172878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease.
    Douros A; Cui Y; Platt RW; Filion KB; Sebastiani G; Renoux C
    Br J Clin Pharmacol; 2022 Mar; 88(3):994-1009. PubMed ID: 34409636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.
    Papp T; Kiss Z; Rokszin G; Fábián I; Márk L; Bagoly Z; Becker D; Merkely B; Aradi D; Dézsi CA; Járai Z; Csanádi Z
    Clin Ther; 2023 Apr; 45(4):333-346. PubMed ID: 37028991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
    Lorenzoni V; Pirri S; Turchetti G
    Clin Drug Investig; 2021 Mar; 41(3):255-267. PubMed ID: 33587284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral anticoagulant switching in patients with atrial fibrillation: a scoping review.
    Adelakun AR; Turgeon RD; De Vera MA; McGrail K; Loewen PS
    BMJ Open; 2023 Apr; 13(4):e071907. PubMed ID: 37185198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation.
    Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A
    J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis.
    Noviyani R; Youngkong S; Nathisuwan S; Bagepally BS; Chaikledkaew U; Chaiyakunapruk N; McKay G; Sritara P; Attia J; Thakkinstian A
    BMJ Evid Based Med; 2022 Aug; 27(4):215-223. PubMed ID: 34635480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
    See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.
    Bayer V; Kotalczyk A; Kea B; Teutsch C; Larsen P; Button D; Huisman MV; Lip GYH; Olshansky B
    J Am Heart Assoc; 2022 Mar; 11(6):e023907. PubMed ID: 35243870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation.
    Ferroni E; Gennaro N; Costa G; Fedeli U; Denas G; Pengo V; Corti MC
    Int J Cardiol; 2019 Aug; 288():72-75. PubMed ID: 31043323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort.
    Aebersold H; Foster-Witassek F; Aeschbacher S; Beer JH; Blozik E; Blum M; Bonati L; Conte G; Coslovsky M; De Perna ML; Di Valentino M; Felder S; Huber CA; Moschovitis G; Mueller A; Paladini RE; Reichlin T; Rodondi N; Stauber A; Sticherling C; Szucs TD; Conen D; Kuhne M; Osswald S; Schwenkglenks M; Serra-Burriel M;
    Open Heart; 2024 Jan; 11(1):. PubMed ID: 38302139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy and safety between VKAs and DOACs in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis.
    Yan J; Liu M; Zhang Y; Yang D; An F
    Clin Cardiol; 2022 Oct; 45(10):1002-1010. PubMed ID: 36030549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation.
    Contreras Muruaga MDM; Vivancos J; Reig G; González A; Cardona P; Ramírez-Moreno JM; Martí J; Suárez Fernández C;
    J Comp Eff Res; 2017 Jun; 6(4):303-312. PubMed ID: 28353372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data.
    Hirschl M; Kundi M
    Vasa; 2019 Mar; 48(2):134-147. PubMed ID: 30376416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.
    Archontakis-Barakakis P; Li W; Kalaitzoglou D; Tzelves L; Manolopoulos A; Giannopoulos S; Giamouzis G; Giannakoulas G; Batsidis A; Palaiodimos L; Ntaios G; Lip GYH; Kokkinidis DG
    Br J Clin Pharmacol; 2022 Nov; 88(11):4663-4675. PubMed ID: 35853612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation.
    Souverein PC; van den Ham HA; Huerta C; Merino EM; Montero D; León-Muñoz LM; Schmiedl S; Heeke A; Rottenkolber M; Andersen M; Aakjaer M; De Bruin ML; Klungel OH; Gardarsdottir H
    Br J Clin Pharmacol; 2021 Mar; 87(3):988-1000. PubMed ID: 32627222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.